How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,795 results for

Urine Uric Acid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

361. Zingerone alleviates the delayed ventricular repolarization and AV conduction in diabetes: Effect on cardiac fibrosis and inflammation. Full Text available with Trip Pro

prevented the decrease in of the serum anti-inflammatory cytokine adiponectin in diabetics. The heightened levels of oxidative stress markers 8-isoprostane and uric acid in diabetic rats were suppressed. In the diabetic heart, the reduced catalase activity was improved and the excessive expression of angiotensin receptor 1 was inhibited by zingerone.Cardiac delayed repolarisation and AV conduction in rats with diabetes were halted by zingerone. It appears that inhibition of cardiac fibrosis (...) Zingerone alleviates the delayed ventricular repolarization and AV conduction in diabetes: Effect on cardiac fibrosis and inflammation. The study aims to analyse the action of zingerone in diabetes-related cardiac arrhythmias.Diabetes was induced by streptozocin while treatment groups received 20 mg/kg zingerone daily. Following extra seven weeks, electrocardiography, extraction of blood, urine and heart for biochemical analysis, histopathology and immunofluorescence were undertaken.The

2017 PLoS ONE

362. Point mutation in D8C domain of Tamm-Horsfall protein/uromodulin in transgenic mice causes progressive renal damage and hyperuricemia. Full Text available with Trip Pro

in kidneys' thick ascending limb (TAL) caused unfolded protein response in younger (1-month old) mice and apoptosis in older (12-month old) mice. While the young mice had urine concentration defects and polyuria, such defects progressively reversed in the older mice to marked oliguria, highly concentrated urine, fibrotic kidneys and reduced creatinine clearance. Both the young and the old transgenic mice had significantly higher serum uric acid and its catabolic product, allantoin, than age-matched wild

2017 PLoS ONE

363. Diagnostic accuracy of third-generation dual-source dual-energy CT: a prospective trial and protocol for clinical implementation. (Abstract)

Diagnostic accuracy of third-generation dual-source dual-energy CT: a prospective trial and protocol for clinical implementation. Uric acid (UA) calculi can be referred to chemolitholysis rather than invasive treatment. Dual-energy computed tomography (DECT) may be able to distinguish between UA and non-UA (NUA) calculi. The aim of this study was to evaluate the validity of third-generation DECT for the first time and to investigate whether combining DECT with clinical parameters can increase (...) urinary stones, 10 (11.9%) patients had UA stones according to infrared spectrometry, and the remaining stones were NUA or mixed stones. DECT had a positive predictive value of 100% and a negative predictive value of 98.5% for UA stones. The AUC for urine pH alone was 0.71 and 0.97 for DECT plus urine pH. No UA stones were found in patients with a urine pH above > 5.5. Mean DLP was 225.15 ± 128.60 mGy*cm and mean effective dose was 3.38 ± 1.93 mSv.DECT is a safe method for assigning patients to oral

2018 World journal of urology

364. Determinants of hyperuricemia in non-dialysed chronic kidney disease patients in three hospitals in Cameroon. Full Text available with Trip Pro

limited countries. We sought to determine the prevalence and factors associated with hyperuricemia in non-dialysed CKD adult patients in Cameroon.This was a cross-sectional study of non-dialysed CKD patients, conducted in 3 referral nephrology units in Cameroon. Relevant clinical and laboratory data were collected using interviewer-administered questionnaires. Serum uric acid, spot urine protein and spot urine creatinine were assessed. Associations between variables were assessed using multivariate (...) analysis. Level of statistical significance was set at α < 0.05.A sample of 103 participants was included. Mean age of study participants was 55.78 ± 12.58 years, and 59.3% were men. Sixty-nine (67%) had hyperuricemia. Patient's age (OR: 1.08, 95% CI: 1.03-1.13), estimated glomerular filtration rate (OR: 0.94, 95% CI: 0.90-0.98), spot urine protein-creatinine ratio (OR: 1.83, 95% CI: 1.07-3.12), no hypertension (OR: 0.09, 95% CI: 0.02-0.46), urate lowering therapy (OR: 4.99, 95% CI: 1.54-16.16), loop

2018 BMC Nephrology

365. A heterozygous variant in the SLC22A12 gene in a Sri Lanka family associated with mild renal hypouricemia. Full Text available with Trip Pro

A heterozygous variant in the SLC22A12 gene in a Sri Lanka family associated with mild renal hypouricemia. Renal hypouricemia is a rare heterogeneous inherited disorder characterized by impaired tubular uric acid transport, reabsorption insufficiency and /or acceleration of secretion. The affected individuals are predisposed to nephrolithiasis and recurrent episodes of exercise-induced acute kidney injury. Type 1 is caused by dysfunctional variants in the SLC22A12 gene (URAT1), while type 2 (...) is caused by defects in the SLC2A9 gene (GLUT9). To date, more than 150 patients with the loss-of-function mutations for the SLC22A12 gene have been found (compound heterozygotes and/or homozygotes), most of whom are Japanese and Koreans.Herein, we report a nine year old Sri Lankan boy with renal hypouricemia (serum uric acid 97 μmol/L, fractional excretion of uric acid 33%).The sequencing analysis of SLC22A12 revealed a potentially deleterious missense variant c.1400C > T (p.T467 M, rs200104135

2018 BMC Pediatrics

366. Menopause and Risk of Kidney Stones. Full Text available with Trip Pro

menopause was 1.27 (95% CI 1.09-1.48) and 1.43 (95% CI 1.19-1.73), respectively. Among the 74,505 postmenopausal participants there was a total of 1,041 incident stone events. Compared with no hormone therapy neither current nor past use was significantly associated with kidney stone risk. Compared with premenopause the postmenopausal urine collections had lower mean calcium, citrate, phosphorus and uric acid, and higher mean volume.Postmenopausal status is associated with a higher risk of incident (...) Menopause and Risk of Kidney Stones. Metabolic changes due to menopause may alter urine composition and kidney stone risk but results of prior work on this association have been mixed. We examined menopause and the risk of incident kidney stones, and changes in 24-hour urine composition in the NHS (Nurses' Health Study) II.Using multivariate adjusted Cox proportional hazards models we prospectively analyzed 108,639 NHS II participants who provided information on menopause and kidney stones. We

2018 Journal of Urology

367. Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial. Full Text available with Trip Pro

Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial. Uric acid may activate an innate immune response in osteoarthritis (OA), contributing to disease pathology and progression. We evaluated the effectiveness of colchicine on pain and function in symptomatic knee OA (KOA) and the underlying mechanism of action.Colchicine effectiveness in symptoms and inflammation modification in knee osteoarthritis (COLKOA (...) in serum, urine, synovial fluid (SF) biomarkers of cartilage metabolism and inflammation, and plasma/SF colchicine concentrations.Of 109 randomly assigned participants, 39% (95% confidence interval (CI) 27-52%) and 49% (95% CI 36-62%) in the colchicine and placebo arms respectively met the primary endpoint at study end (P = 0.284, odds ratio 0.66, 95% CI 0.31-1.41). No strong evidence of treatment differences was identified on clinical secondary endpoints. Treatment significantly reduced mean serum hs

2018 Osteoarthritis and Cartilage Controlled trial quality: predicted high

368. Comparison of potential dietary and urinary risk factors for ammonium urate nephrolithiasis in two bottlenose dolphin (Tursiops truncatus) populations. Full Text available with Trip Pro

, and physicochemical parameters via Wilcoxon rank sum analysis and least square means. Managed dolphins had higher urinary pH and ammonium ([Formula: see text]) in both pre- and postprandial conditions and higher urinary uric acid and saturation indices of NH4U in the postprandial condition compared with free-ranging dolphins ( P < 0.05). The purine content was greater ( P < 0.0001) in the diet consumed by managed dolphins [7 mmol/Mcal metabolizable energy (ME)] than in the free-ranging dolphin diet (4 mmol/Mcal (...) Comparison of potential dietary and urinary risk factors for ammonium urate nephrolithiasis in two bottlenose dolphin (Tursiops truncatus) populations. Dietary and urinary risk factors have been implicated in conditions favoring ammonium urate nephrolithiasis in managed dolphins compared with free-ranging dolphins. In this study, urine samples were collected from 16 dolphins (8 cases, 8 controls) from the U.S. Navy Marine Mammal Program for the purposes of assessing changes in urinary

2018 American Journal of Physiology. Renal physiology

369. The PK/PD Study of SHR0532 Tablets in Healthy Subjects

>20mmHg; A clinical history of arrhythmia;subjects with Electrocardiogram QTc prolongation(male>450ms;female>460ms)during screening; A clinical history of hyperuricemia;serum uric acid > the upper limit of normal value (ULN) during screening; A clinical history of diabetes;fasting plasma glucose or hemoglobin A1c exceeded the upper limit of normal value (ULN) during screening; Subjects with previous GI discomfort -abdominal pain, diarrhea, and nausea 3 months prior to screening; A clinical history (...) after oral administration (CL/F) of SHR-0532 [ Time Frame: Pre-dose to 5 days after dose administration ] Apparent volume of distribution after non-intravenous administration (V/F) of SHR-0532 [ Time Frame: Pre-dose to 5 days after dose administration ] Renal clearance of the drug from plasma (CLR) of SHR-0532 [ Time Frame: Pre-dose to 5 days after dose administration ] Cumulative amount of unchanged drug excreted into the urine(Ae) of SHR-0532 [ Time Frame: Pre-dose to 5 days after dose

2018 Clinical Trials

370. A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

Frame: At screening, throughout the treatment periods till follow-up or discontinuation. ] To assess serum albumin level as a variable of safety and tolerability after administration of inhaled AZD8871 600 µg. Laboratory assessments: Serum clinical chemistry - Uric acid and Blood urea nitrogen (BUN) [ Time Frame: At screening, throughout the treatment periods till follow-up (42 days after visit 11 or last IP administration) or discontinuation. ] To assess serum uric acid and BUN level as a variable (...) serum creatine kinase level as a variable of safety and tolerability after administration of inhaled AZD8871 600 µg. Laboratory assessments: Clinical Urinalysis - pH [ Time Frame: At screening, throughout the treatment periods till follow-up (42 days after visit 11 or last IP administration) or discontinuation. ] To assess urine pH as a variable of safety and tolerability after administration of inhaled AZD8871 600 µg. Laboratory assessments: Clinical Urinalysis - Blood [ Time Frame: At screening

2018 Clinical Trials

371. Renal Hemodynamics in Patients With HFpEF

in dyn x sec x cm^-5 Intraglomerular pressure [ Time Frame: One week after study inclusion ] in mmHg Biospecimen Retention: Samples Without DNA Biochemistry (urea, serum creatinine, eGFR, cystatin C, uric acid, sodium, potassium, calcium, phosphate, lipid levels, total protein, SGOT, SGPT, AP, ɣ-GT) Hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count) Fasting blood glucose, HbA1c NT-proBNP TSH Spot-urine (urinary creatinine and albumin, urinary sodium (...) with sodium p-aminohippuric acid (PAH) and Iohexol in 40 patients with HFpEF. The constant infusion input clearance technique offers an exact evaluation of renal function by measuring (not estimating) glomerular filtration rate and renal hemodynamic parameters such as renal plasma flow (RPF), filtration fraction (FF) and intraglomerular pressure (IGP). These results will be compared to 140 subjects without HFpEF that have participated in various studies and have been analyzed with the same constant

2018 Clinical Trials

372. Short-term Supplementation, Bone Turnover and Antioxidant Status in Menopause

[ Time Frame: 2 months ] Biochemistry was performed after 12 hours of fasting first thing in the morning, by specialists puncturing the cubital vena cava (Venoject®). The following measurements were taken: Glucose (mg/dL), creatinine (mg/dL), urea (mg/dL), uric acid (mg/dL), triglycerides (mg/dL), total cholesterol (mg/dL), total proteins (g/dL), transferrin (mg/dL) and albumin (mg/dL). Hormonal parameters [ Time Frame: 2 months ] Hormonal parameters were performed after 12 hours of fasting first (...) hours prior to the measurement, and no urination immediately before the measurement. All measurements were taken simultaneously during the morning in fasting conditions. The following measurements were taken: weight, body mass index (calculated as weight/height^2 and expressed kg/m2) and fat mass (expressed in kilograms and as the percentage of body fat), fat free mass (expressed in kilograms and as the percentage of fat free mass), muscle mass (expressed in kilograms). Intake assessment [ Time

2018 Clinical Trials

373. Gene Expression in Intervened Athletes

(Venoject®). Creatinine was measured and expressed in mg/dL. The reference value is established in 0.5 - 0.9 mg/dL. Biochemical parameters - Urea [ Time Frame: At baseline ] Biochemistry was performed after 12 hours of fasting first thing in the morning, by specialists puncturing the cubital vena cava (Venoject®). Urea was measured and expressed in mg/dL. The reference value is established in 10 - 50 mg/dL. Biochemical parameters - Uric acid [ Time Frame: At baseline ] Biochemistry was performed after (...) 12 hours of fasting first thing in the morning, by specialists puncturing the cubital vena cava (Venoject®). Uric acid was measured and expressed in mg/dL. The reference value is established in 2.4 - 5.7 mg/dL. Biochemical parameters - Triglycerides [ Time Frame: At baseline ] Biochemistry was performed after 12 hours of fasting first thing in the morning, by specialists puncturing the cubital vena cava (Venoject®). Triglycerides acid was measured and expressed in mg/dL. The reference value

2018 Clinical Trials

374. Evaluation of Nephureâ„¢, and the Reduction of Dietary Oxalate, in Healthy Volunteers

: www.niddk.nih.gov/health-information/communication-programs/nkdep/laboratory-evaluation/glomerular-filtration-rate-calculators/ckd-epi-adults-conventional-units.) Subject has a urinary oxalate <40.5mg/24 hours at the time of Screening . Subject has a urinary uric acid <750mg/24hour at the time of Screening1. Subject is in good health as determined by complete physical examination, medical history, vital signs, and laboratory tests. Subject is able to understand the study and be able to comply (...) to the requirements and restrictions, including agreeing to complete the 24-hour urine collections, and has the ability to report their symptoms. Subject is able to comply with all dietary expectations and fluid intake at the discretion of the Principal Investigator (PI). Female subjects must agree to use an acceptable form of birth control from screening through the duration of the study (unless otherwise stated). See section 5.1.1. Exclusion Criteria: Subject has a history or presence of clinically significant

2018 Clinical Trials

375. Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy

Study Completion Date : September 2019 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: cases laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels Diagnostic Test: renal arterial resistive index done by dupplex on renal arteries Diagnostic (...) Test: uric acid level serum sample for doing the test Diagnostic Test: serum urea and creatinine serum samples for doing the test Diagnostic Test: 24 hours urinary proteins urine collected over 24 hours for doing the test Diagnostic Test: lipogram serum sample for doing the test Other Name: lipid profile Diagnostic Test: HbA1c level serum sample for doing the test Diagnostic Test: urine analysis urine sample for doing the test Diagnostic Test: abdominal ultrasonography done by the ultrasonography

2018 Clinical Trials

376. Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease

(>1.5*ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (>3*ULN), total protein, albumin (<0.8*LLN/>1.2*ULN); creatinine, urea (>1.3*ULN); glucose (<0.6*LLN/>1.5*ULN); uric acid (>1.2*ULN); sodium, potassium, chloride, calcium, bicarbonate (<0.9*LLN/>1.1*ULN); urine red blood cells (RBCs), urine white blood cells (WBCs), urine epithelial cells (>=6 high-powered field), urine bacteria >20 high-powered field; qualitative urine glucose, ketones, protein values (...) , urea (>1.3*ULN); glucose (<0.6*LLN/>1.5*ULN); uric acid (>1.2*ULN); sodium, potassium, chloride, calcium, bicarbonate (<0.9*LLN/>1.1*ULN); urine red blood cells (RBCs), urine white blood cells (WBCs), urine epithelial cells (>=6 high-powered field), urine bacteria >20 high-powered field; qualitative urine glucose, ketones, protein values >=1 in urine dipstick test. Total number of participants with any laboratory abnormalities was reported. Change From Baseline in Audiological Examinations at Week

2018 Clinical Trials

377. Study to Evaluate Benefit of ProbioSatysâ„¢ on Weight Reduction in Overweight Subjects

to screening values (V1) [ Time Frame: 14 weeks ] liver and renal function parameters (uric acid) Global evaluation of tolerability at V5 by subject and the investigator [ Time Frame: 12 weeks ] "very good", "good", "moderate" and "poor" Gastrointestinal tolerability parameters (Gastrointestinal Symptom Rating Scale questionnaire, GSRS), compared to baseline [ Time Frame: 4, 8 and 12 weeks ] Stool frequency in the week before each visit post- baseline, each compared to the week before baseline (V2) [ Time (...) : Follow diet recommendation Maintain the habitual level of physical activity during the study Fill out the questionnaires and subject diary Take the IP as instructed Stable body weight in the last 3 months prior to V1 (≤5% self-reported change) Stable concomitant medications (if any) for at least last 3 months prior to V1 Women of childbearing potential: Negative pregnancy testing (beta HCG-test in urine) at V1 Women of childbearing potential: commitment to use contraception methods

2018 Clinical Trials

378. Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol Acetate

corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, erythrocyte distribution width, platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils. Blood chemistry 27 elements: glucose, urea, blood urea nitrogen (BUN), creatinine, BUN/creatinine ratio, uric acid, cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, low-density lipoprotein (LDL), cholesterol, non-HDL cholesterol, atherogenic index, total protein, albumin, globulins, albumin (...) , casts, crystals, squamous epithelial cells, tubular renal cells, mucus, bacteria and yeasts). Hepatitis B screening (Antibody to hepatitis B core antigen [Anti-HBc], antibody to hepatitis B surface antigen [HBs-Ab], antibody to hepatitis B surface antigen [Anti-HBs]) and hepatitis C antibodies. HIV test: Antibodies to the human immunodeficiency virus (Anti-HIV 1 and 2). Venereal disease research laboratory test (VDRL). Urine drugs of abuse test at the screening visit and on Day 0 (approximately 12

2018 Clinical Trials

379. Characterization of the Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women

corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, erythrocyte distribution width, platelets, neutrophils, lymphocytes, monocytes, eosinophils. Blood chemistry 27 elements: glucose, urea, blood urea nitrogen (BUN), creatinine, BUN/creatinine ratio, uric acid, cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, low-density lipoprotein cholesterol, non-HDL cholesterol, atherogenic index, total protein, albumin, globulins, albumin/globulin ratio (...) 450 milliliters of blood within 60 days prior to study start. M. Participants with a history of drug abuse or alcoholism. N. Participants requiring a special diet for any reason e.g., vegetarian. O. Participants unable to understand the nature, objectives, and possible consequences of the study. P. Evidence of the participant's uncooperativeness during the conduct of the study. Q. Positive results for drugs of abuse (in urine) or alcohol breath tests. R. Participants who are not registered

2018 Clinical Trials

380. Pharmacokinetics of Two Formulation of Pregabalin

as AST), Serum Glutamic Pyruvic Transaminase (SGPT, same as ALT), Gamma-Glutamyl-Transpeptidase (γ-GT), alkaline phosphatase, total bilirubin, albumin, glucose, Blood Urea Nitrogen(BUN), uric acid, creatinine, total cholesterol and triglyceride (TG). Acceptable hematology (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to study drug dosing, which includes hemoglobin, hematocrit, red blood cell count, white blood cell (...) two years or history of gastrointestinal tract surgery over last five years. History of kidney disease or urination problem over last two years deemed by the investigator to be clinically significant. Known or suspected history of drug abuse within lifetime as judged by the investigator. History of alcohol addiction or abuse within last five years as judged by the investigator. History of allergic response(s) to pregabalin or any other related drugs. Evidence of chronic or acute infectious

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>